Research Analysts’ Weekly Ratings Changes for TransMedics Group (TMDX)

Several brokerages have updated their recommendations and price targets on shares of TransMedics Group (NASDAQ: TMDX) in the last few weeks:

• 10/29/2024 – TransMedics Group had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $180.00 price target on the stock.
• 10/29/2024 – TransMedics Group had its price target lowered by analysts at JPMorgan Chase & Co. from $173.00 to $116.00. They now have an “overweight” rating on the stock.
• 10/29/2024 – TransMedics Group had its price target lowered by analysts at Robert W. Baird from $200.00 to $150.00. They now have an “outperform” rating on the stock.
• 10/29/2024 – TransMedics Group had its price target lowered by analysts at Oppenheimer Holdings Inc. from $200.00 to $125.00. They now have an “outperform” rating on the stock.
• 10/29/2024 – TransMedics Group had its price target lowered by analysts at Canaccord Genuity Group Inc. from $169.00 to $109.00. They now have a “buy” rating on the stock.
• 10/29/2024 – TransMedics Group had its price target lowered by analysts at Needham & Company LLC from $208.00 to $109.00. They now have a “buy” rating on the stock.
• 10/7/2024 – TransMedics Group had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $180.00 price target on the stock.
• 9/24/2024 – TransMedics Group was upgraded by analysts at Baird R W to a “strong-buy” rating.
• 9/24/2024 – TransMedics Group is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $200.00 price target on the stock.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $81.97 on Friday. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of 87.20 and a beta of 1.99. The company has a 50 day moving average of $142.38 and a 200-day moving average of $139.36. The company has a current ratio of 8.20, a quick ratio of 8.48 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period in the previous year, the business posted ($0.12) EPS. The business’s quarterly revenue was up 63.7% on a year-over-year basis. On average, equities analysts forecast that TransMedics Group, Inc. will post 1.11 earnings per share for the current fiscal year.

Insider Activity

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the completion of the sale, the director now owns 732 shares in the company, valued at approximately $109,770.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock valued at $9,518,181 over the last three months. 7.00% of the stock is owned by insiders.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in TMDX. Fidelis Capital Partners LLC acquired a new stake in shares of TransMedics Group during the first quarter worth $35,000. International Assets Investment Management LLC acquired a new stake in TransMedics Group in the 2nd quarter valued at $47,000. USA Financial Formulas acquired a new stake in TransMedics Group in the 3rd quarter valued at $55,000. J.Safra Asset Management Corp increased its stake in TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the last quarter. Finally, Signaturefd LLC increased its stake in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.